Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in developing cancer treatment products specifically designed for women in the USA. Their current primary focus is onapristone extended release (ONA-XR), a powerful antagonist of the progesterone receptor that fights cancer resistance across female hormone-dependent cancers, and CLDN6xCD3 bsAb, a bispecific monoclonal antibody that targets malignant cells expressing CLDN6. The company also has a collaboration and licensing agreement with Integral Molecular, Inc. to develop an anti-claudin 6 bispecific monoclonal antibody to treat gynecologic cancer.